Tags

Type your tag names separated by a space and hit enter

A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.
Breast Cancer Res. 2008; 10(5):R74.BC

Abstract

INTRODUCTION

Estrogen receptor-alpha (ER-alpha) and progesterone receptor (PgR) are consolidated predictors of response to hormonal therapy (HT). In contrast, little information regarding the role of estrogen receptor-beta (ER-beta) in various breast cancer risk groups treated with different therapeutic regimens is available. In particular, there are no data concerning ER-beta distribution within the novel molecular breast cancer subtypes luminal A (LA) and luminal B (LB), HER2 (HS), and triple-negative (TN).

METHODS

We conducted an observational prospective study using immunohistochemistry to evaluate ER-beta expression in 936 breast carcinomas. Associations with conventional biopathological factors and with molecular subtypes were analyzed by multiple correspondence analysis (MCA), while univariate and multivariate Cox regression analysis and classification and regression tree analysis were applied to determine the impact of ER-beta on disease-free survival in the 728 patients with complete follow-up data.

RESULTS

ER-beta evenly distributes (55.5%) across the four molecular breast cancer subtypes, confirming the lack of correlation between ER-beta and classical prognosticators. However, the relationships among the biopathological factors, analyzed by MCA, showed that ER-beta positivity is located in the quadrant containing more aggressive phenotypes such as HER2 and TN or ER-alpha/PgR/Bcl2- tumors. Kaplan-Meier curves and Cox regression analysis identified ER-beta as a significant discriminating factor for disease-free survival both in the node-negative LA (P = 0.02) subgroup, where it is predictive of response to HT, and in the node-positive LB (P = 0.04) group, where, in association with PgR negativity, it conveys a higher risk of relapse.

CONCLUSION

Our data indicated that, in contrast to node-negative patients, in node-positive breast cancer patients, ER-beta positivity appears to be a biomarker related to a more aggressive clinical course. In this context, further investigations are necessary to better assess the role of the different ER-beta isoforms.

Authors+Show Affiliations

Pathology Department, Regina Elena Cancer Institute, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18771580

Citation

Novelli, Flavia, et al. "A Divergent Role for Estrogen Receptor-beta in Node-positive and Node-negative Breast Cancer Classified According to Molecular Subtypes: an Observational Prospective Study." Breast Cancer Research : BCR, vol. 10, no. 5, 2008, pp. R74.
Novelli F, Milella M, Melucci E, et al. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res. 2008;10(5):R74.
Novelli, F., Milella, M., Melucci, E., Di Benedetto, A., Sperduti, I., Perrone-Donnorso, R., Perracchio, L., Venturo, I., Nisticò, C., Fabi, A., Buglioni, S., Natali, P. G., & Mottolese, M. (2008). A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Research : BCR, 10(5), R74. https://doi.org/10.1186/bcr2139
Novelli F, et al. A Divergent Role for Estrogen Receptor-beta in Node-positive and Node-negative Breast Cancer Classified According to Molecular Subtypes: an Observational Prospective Study. Breast Cancer Res. 2008;10(5):R74. PubMed PMID: 18771580.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. AU - Novelli,Flavia, AU - Milella,Michele, AU - Melucci,Elisa, AU - Di Benedetto,Anna, AU - Sperduti,Isabella, AU - Perrone-Donnorso,Raffaele, AU - Perracchio,Letizia, AU - Venturo,Irene, AU - Nisticò,Cecilia, AU - Fabi,Alessandra, AU - Buglioni,Simonetta, AU - Natali,Pier Giorgio, AU - Mottolese,Marcella, Y1 - 2008/09/04/ PY - 2008/01/14/received PY - 2008/07/09/revised PY - 2008/09/04/accepted PY - 2008/9/6/pubmed PY - 2009/2/6/medline PY - 2008/9/6/entrez SP - R74 EP - R74 JF - Breast cancer research : BCR JO - Breast Cancer Res VL - 10 IS - 5 N2 - INTRODUCTION: Estrogen receptor-alpha (ER-alpha) and progesterone receptor (PgR) are consolidated predictors of response to hormonal therapy (HT). In contrast, little information regarding the role of estrogen receptor-beta (ER-beta) in various breast cancer risk groups treated with different therapeutic regimens is available. In particular, there are no data concerning ER-beta distribution within the novel molecular breast cancer subtypes luminal A (LA) and luminal B (LB), HER2 (HS), and triple-negative (TN). METHODS: We conducted an observational prospective study using immunohistochemistry to evaluate ER-beta expression in 936 breast carcinomas. Associations with conventional biopathological factors and with molecular subtypes were analyzed by multiple correspondence analysis (MCA), while univariate and multivariate Cox regression analysis and classification and regression tree analysis were applied to determine the impact of ER-beta on disease-free survival in the 728 patients with complete follow-up data. RESULTS: ER-beta evenly distributes (55.5%) across the four molecular breast cancer subtypes, confirming the lack of correlation between ER-beta and classical prognosticators. However, the relationships among the biopathological factors, analyzed by MCA, showed that ER-beta positivity is located in the quadrant containing more aggressive phenotypes such as HER2 and TN or ER-alpha/PgR/Bcl2- tumors. Kaplan-Meier curves and Cox regression analysis identified ER-beta as a significant discriminating factor for disease-free survival both in the node-negative LA (P = 0.02) subgroup, where it is predictive of response to HT, and in the node-positive LB (P = 0.04) group, where, in association with PgR negativity, it conveys a higher risk of relapse. CONCLUSION: Our data indicated that, in contrast to node-negative patients, in node-positive breast cancer patients, ER-beta positivity appears to be a biomarker related to a more aggressive clinical course. In this context, further investigations are necessary to better assess the role of the different ER-beta isoforms. SN - 1465-542X UR - https://www.unboundmedicine.com/medline/citation/18771580/A_divergent_role_for_estrogen_receptor_beta_in_node_positive_and_node_negative_breast_cancer_classified_according_to_molecular_subtypes:_an_observational_prospective_study_ L2 - https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2139 DB - PRIME DP - Unbound Medicine ER -